Literature DB >> 2398265

Drug metabolism in end-stage liver disease. In vitro activities of some phase I and phase II enzymes.

S Iqbal1, C Vickers, E Elias.   

Abstract

The activities of a number of drug metabolising enzymes were measured in liver samples obtained from three groups of subjects: normal donors, patients with primary biliary cirrhosis (PBC), and patients with other types of liver disease. In the latter group, all the enzyme activities determined were impaired relative to the normal group. In the PBC group, however, enzyme activities were altered more selectively. (a) Activities of the methyl cholanthrene-inducible forms of cytochrome P-450 were decreased compared to normal controls, whereas the activities of the phenobarbitone-inducible isozymes were relatively unaffected. (b) Sulfotransferase activities were decreased significantly compared to the normal group, whereas sulfatase activities remained unaltered.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2398265     DOI: 10.1016/0168-8278(90)90269-w

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  12 in total

1.  Substrate inhibition in human hydroxysteroid sulfotransferase SULT2A1: studies on the formation of catalytically non-productive enzyme complexes.

Authors:  Hayrettin Ozan Gulcan; Michael W Duffel
Journal:  Arch Biochem Biophys       Date:  2010-12-25       Impact factor: 4.013

Review 2.  Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance.

Authors:  Christoph G Dietrich; Oliver Götze; Andreas Geier
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 3.  Dose adjustment in patients with liver disease.

Authors:  Fabiola Delcò; Lydia Tchambaz; Raymond Schlienger; Jürgen Drewe; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 4.  Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.

Authors:  G K Dresser; J D Spence; D G Bailey
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

5.  Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR).

Authors:  Junichiro Sonoda; Wen Xie; John M Rosenfeld; Joyce L Barwick; Philip S Guzelian; Ronald M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

6.  Plasma hydroxy-metronidazole/metronidazole ratio in patients with liver disease and in healthy volunteers.

Authors:  M N Muscará; J Pedrazzoli; E L Miranda; J G Ferraz; E Hofstätter; G Leite; A F Magalhães; S Leonardi; G De Nucci
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

7.  Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments.

Authors:  Fiona V Bϋdingen; Daniel Gonzalez; Amelia N Tucker; Hartmut Derendorf
Journal:  Ther Adv Infect Dis       Date:  2014-02-01

8.  Relationship between differential hepatic microRNA expression and decreased hepatic cytochrome P450 3A activity in cirrhosis.

Authors:  Raj Vuppalanchi; Tiebing Liang; Chirayu Pankaj Goswami; Rohit Nalamasu; Lang Li; David Jones; Rongrong Wei; Wanqing Liu; Vishal Sarasani; Sarath Chandra Janga; Naga Chalasani
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

9.  Changes in cytochrome P450s-mediated drug clearance in patients with hepatocellular carcinoma in vitro and in vivo: a bottom-up approach.

Authors:  Jie Gao; Jun Zhou; Xiao-Pei He; Yun-Fei Zhang; Na Gao; Xin Tian; Yan Fang; Qiang Wen; Lin-Jing Jia; Han Jin; Hai-Ling Qiao
Journal:  Oncotarget       Date:  2016-05-10

10.  Liver Expression of Sulphotransferase 2A1 Enzyme Is Impaired in Patients with Primary Sclerosing Cholangitis: Lack of the Response to Enhanced Expression of PXR.

Authors:  Ewa Wunsch; Marta Klak; Urszula Wasik; Malgorzata Milkiewicz; Malgorzata Blatkiewicz; Elzbieta Urasinska; Olivier Barbier; Dariusz Bielicki; Dimitrios P Bogdanos; Elwyn Elias; Piotr Milkiewicz
Journal:  J Immunol Res       Date:  2015-10-04       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.